Subtype and pathway specific responses to anticancer compounds in breast cancerLaura M. Heiser, Paul T. Spellman, Theodore C. Goldstein et al.|Proceedings of the National Academy of Sciences|2011Cited by 505
Pharmacodynamic monitoring of BAY 43‐9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cellsFrances Tong, David W. Hedley|Cytometry Part B Clinical Cytometry|2006Cited by 52